Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
19 March 2025
In the News
Mark Neuberger Featured for Legal Career, Pro Bono Service
Foley & Lardner LLP of counsel Mark Neuberger is featured by Biscayne Bay Tribune for his distinguished legal career and commitment to pro bono service in the article, “From the Boardroom to the Arts: Mark Neuberger’s Unique Approach to Law.”
18 March 2025
In the News
Foley Attorneys Featured for Arrival to Miami Office
Foley & Lardner LLP partners Vanessa Singh Johannes and Charles Throckmorton are featured for their recent arrival to the firm alongside associates Samantha Goldstein and Holli Gray in the Daily Business Review article, “Foley & Lardner Poaches Team of 4, Including Miami Office Leader, From Carlton Fields.”
18 March 2025
In the News
Chanley Howell Assesses Virginia AI Legislation
Foley & Lardner LLP partner Chanley Howell shared important context on the growing movement to regulate artificial intelligence at the state level in the Law360 article, "3 State AI Bills For Workplace Discrimination Attys To Watch."